PlateletBio
Financing Rounds
- Series B
- Exit
Round Led by Symbiosis
Round Led by Symbiosis
Inspired by the biological function and versatility of platelets, PlateletBio is pioneering the next generation of safer, more effective cell therapies. Its cell therapy platform produces “platelet-like cells” (PLCs) capable of performing vital biological functions and able to be genetically engineered into multiple allogeneic cell therapies. The Company is focused on advancing a diverse pipeline of next-generation cellular therapies for applications in autoimmune diseases, hematology, and inflammation.
View Website
Modality
- Cell Therapy
Indication
- Immunology
Development Status
- Pre-Clinical